Percutaneous Renal Denervation: A New Promise in the Treatment of RHT?
|
|
- Tiffany Wiggins
- 6 years ago
- Views:
Transcription
1 BAD KROZINGEN Prof. T. Zeller, MD Bad Krozingen, Germany Percutaneous Renal Denervation: A New Promise in the Treatment of RHT?
2 Potential conflicts of interest Speaker s name: Thomas Zeller X I have the following potential conflicts of interest to report: X Research contracts X Consulting Employment in industry Stockholder of a healthcare company Owner of a healthcare company Other(s)
3 Resistant hypertension Resistant Hypertension Definition BP > 140/90 mmhg, despite treatment with 3 drug classes including a diuretic (ESH / ESC) AHA Statement Circulation 2008;117:e510ff
4 Renal Injury Induces Activation of Sensory Efferent Signals CNS Integration Smooth muscle migration Vasoconstriction Atherosclerosis Hypertrophy Arrhythmias Ischemia Heart Failure Renal ischemia Stroke volume Adenosine Renal Afferent Nerves Renin release Systemic sympathetic gain Na+ retention Hypervolemia Wall stiffness Decreased RBF Proteinuria BNP resistance BNP=brain natriuretic peptide; CNS=central nervous system; RAAS=renal-angiotensin-aldosterone system; RBF=renal blood flow. Adapted from Schlaich MP et al. Hypertension. 2009;54:
5 Conceptual Basis for Renal Denervation Neurohormones BP Disrupt the renal nerves, break the cycle Simultaneously reduce both efferent and afferent effects BP=blood pressure. Adapted from Schlaich MP et al. Hypertension. 2009;54:
6 The Renal Denervation Procedure 4-8 focal treatments are delivered 120 seconds per treatment 5 mm between locations Stable, unique locations Circumferential coverage The catheter is pulled, rotated, and new location and prior treatment site are assessed
7 The Symplicity TM Renal Denervation System* Clinical Trial Program Staged Evaluation in Hypertension First-in-man 1 Symplicity HTN-1 2 Series of pilot studies *device not approved for use in the US Symplicity HTN-2 3 EU/AU randomized clinical trial USA Symplicity HTN-3 4 US randomized clinical trial (ongoing) EU/AU Other Areas of Research: 4 Insulin resistance, HF/cardiorenal, OSA, more HF=heart failure; OSA=obstructive sleep apnea. 1. Krum H et al. Lancet. 2009;373: ; 2. Symplicity HTN-1 Investigators. Hypertension. 2011;57: ; 3. Symplicity HTN-2 Investigators. Lancet. 2010;376: ; 4. Data on file, Medtronic, Inc.
8 The Symplicity HTN-1 Trial: Study Design Design Multicenter, international, nonrandomized, open-label, proof-of-concept study Population 153 patients with treatment-resistant hypertension Treatment Endovascular catheter-based renal denervation using the Symplicity Catheter System* plus baseline antihypertensive medications Duration 36 months (assessments at 1, 3, 6, 12, 18, 24, and 36 months) Outcome measures Primary efficacy measure: Change in office BP Primary safety measures: Physical examination, blood chemistries, anatomic assessment of renal vasculature Symplicity HTN-1 Investigators. Hypertension. 2011;57:
9 Symplicity HTN-1 Trial Key Inclusion/Exclusion Criteria Inclusion criteria >18 years Office SBP 160 mm Hg 3 antihypertensive medications (including 1 diuretic) Exclusion criteria egfr <45 ml/min/1.73 m 2 Type 1 diabetes mellitus Known secondary cause of hypertension (other than OSA or CKD) Significant renovascular abnormalities CKD=chronic kidney disease; egfr=estimated glomerular filtration rate; OSA=obstructive sleep apnea; SBP=systolic blood pressure. Symplicity HTN-1 Investigators. Hypertension. 2011;57:
10 Symplicity HTN-1 Trial Demographics of Treated Patients Demographics Mean age ± SD (years) 57 ± 11 Gender (% female) 39 Race (% noncaucasian) 5 Comorbidities Type 2 diabetes mellitus (%) 31 Coronary artery disease (%) 22 Hyperlipidemia (%) 68 Mean egfr ± SD (ml/min/1.73 m 2 ) 83 ± 20 BP Mean baseline BP ± SD (mm Hg) 176/98 ± 17/15 Mean number of antihypertensive medications ± SD 5.1 ± 1.4 Diuretics (%) 95 Aldosterone blockers (%) 22 ACE inhibitors or angiotensin receptor blockers (%) 91 Direct renin inhibitors (%) 14 β-blockers (%) 82 Calcium channel blockers (%) 75 Centrally acting sympatholytics (%) 33 Vasodilators (%) 19 α-1 blockers (%) 19 BP=blood pressure; egfr=estimated glomerular filtration rate. Symplicity HTN-1 Investigators. Hypertension. 2011;57:
11 Procedural safety Symplicity HTN-1: Acute Safety No catheter or generator malfunctions No major complications Minor complications in 4 of 153 patients: 1 renal artery dissection during catheter delivery (prior to RF energy delivery); no sequelae 3 access site complications (pseudoaneurysm/hematoma); treated without sequelae First 20 patients had short-term (14-30 days) follow-up angiography No evidence of renal artery stenosis or other abnormalities RF=radio frequency. Symplicity HTN-1 Investigators. Hypertension. 2011;57:
12 Symplicity HTN-1 Trial: Change in Office Blood Pressure Through 36 Months BP change (mmhg) P<0.01 for from BL for all time points
13 Change in Office Blood Pressure for 24 Patients with 36 Month Follow-up BP change (mmhg) P<0.01 for from BL for all time points Caution: The Symplicity Catheter System is an Investigational Device. Limited by U.S. law to investigational use. For OMA distribution only Medtronic, Inc. All rights reserved DOC_1A 03/2012
14 % Patients Distribution of SBP Change at BL, 1, 12, 24, and 36 Months (N=150) (N=143) (N=130) (N=59) (N=24) Caution: The Symplicity Catheter System is an Investigational Device. Limited by U.S. law to investigational use. For OMA distribution only Medtronic, Inc. All rights reserved DOC_1A 03/2012
15 Chronic Safety Out to 3 Years One progression of a pre-existing stenosis unrelated to RF treatment (stented without further sequelae) One new moderate stenosis which was not hemodynamically relevant and no treatment 3 deaths within the follow-up period; all unrelated to the device or therapy No hypotensive events that required hospitalization There was no significant change in mean electrolytes or egfr Symplicity HTN-1 Investigators. Hypertension. 2011;57:
16 Conclusions The magnitude of clinical response is significant and sustained through 3 years The treatment effect was consistent across subgroups (age, diabetes status, and baseline renal function) No late adverse events were seen Caution: The Symplicity Catheter System is an Investigational Device. Limited by U.S. law to investigational use. For OMA distribution only Medtronic, Inc. All rights reserved DOC_1A 03/2012
17 Symplicity HTN-2: Study Design Multicenter, Randomized, Prospective Trial Renal denervation with previous treatment (n=52) Patients with resistant hypertension Randomization Primary endpoint: Change in seated office SBP at 6 months Maintain previous treatment alone (n=54) SBP=systolic blood pressure. Symplicity HTN-2 Investigators. Lancet. 2010;376:
18 Symplicity HTN-2 Trial Key Inclusion/Exclusion Criteria * Inclusion criteria years of age Elevated office SBP 160 mm Hg (or 150 mm Hg for type 2 diabetics) Documented compliance with 3 antihypertensive medications Exclusion criteria egfr <45 ml/min/1.73m 2 Type 1 diabetes mellitus Contraindications to MRI Substantial stenotic valvular heart disease Pregnancy or planned pregnancy during the study Myocardial infarction, unstable angina, or cerebrovascular accident in the previous 6 months Hemodynamically or anatomically significant renal artery abnormalities or prior renal artery intervention *Inclusion/exclusion criteria in the trial settings were stringent and conservative in order to ensure a homogenous population in clinical practice, individual patient characteristics and physician judgment should guide patient selection. egfr=estimated glomerular filtration rate; MRI=magnetic resonance imaging. Symplicity HTN-2 Investigators. Lancet. 2010;376:
19 Patient Disposition Assessed for Eligibility (n=190) Screening Randomized (n=106) Excluded During Screening, Prior to Randomization (n=84) BP < 160 at Baseline Visit (after 2-weeks of medication compliance confirmation) (n=36; 19%) Ineligible anatomy (n=30; 16%) Declined participation (n=10; 5%) Other exclusion criteria discovered after consent (n=8; 4%) 6-month Primary End-Point Allocated to RDN N=52 Treated N=49 Analyzable Allocated to Control N=54 Control N=51 Analyzable Crossover N=46 (2 LTFU) 12-month Post- Randomization 12-month post-rdn N=47 Per protocol, 6-mo Post RDN (Crossover) N=35 Not-per-protocol*, 6-mo Post RDN (Crossover) N=9 * Crossed-over with ineligible BP (<160 mmhg)
20 Symplicity HTN-2 Trial: BP and Antihypertensive Medication Use at Baseline Symplicity RDN Group (n=52) 1 Control Group (n=54) 1 P 2 BP Mean baseline SBP ± SD (mm Hg) 178 ± ± Antihypertensive Use Mean baseline DBP ± SD (mm Hg) 97 ± ± Mean number of antihypertensive medications ± SD 5.2 ± ± Diuretics (%) Aldosterone blockers (%) >.99 ACE inhibitors, angiotensin receptor blockers (%) >.99 Direct renin inhibitors (%) β-blockers (%) Calcium channel blockers (%) Centrally acting sympatholytics (%) >.99 Vasodilators (%) >.99 α-1 blockers (%) BP=blood pressure; DBP=diastolic blood pressure; RDN=renal denervation; SBP=systolic blood pressure. 1. Symplicity HTN-2 Investigators. Lancet. 2010;376: ; 2. Data on file, Medtronic, Inc.
21 Change in Office Blood Pressure (mm Hg) mo post-rdn* 6-mo post randomization 6-mo Crossover 12- mo post randomization 12-mo post-rdn* Crossover 6-mo post-rdn* RDN SBP RDN DBP Cross over SBP Cross over DBP * P<0.001 for SBP and DBP change from baseline P=0.026 for SBP change from baseline
22 % Patients Distribution of Office SBP for RDN Group 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 180 mm Hg mm Hg mm Hg <140 mm Hg 0% RDN Baseline RDN 6-month RDN 12-month
23 Symplicity HTN-2 Trial: 6-Month Home BP /12 mm Hg difference between Symplicity RDN and control groups (P<.0001) DBP=diastolic blood pressure; RDN=renal denervation; SBP=systolic blood pressure. Symplicity HTN-2 Investigators. Lancet. 2010;376:
24 Patients (%) Symplicity HTN-2: Goal Achievement Renal denervation group Control group (n=41, 84%) 60 (n=24, 47%) P<.0001 for all between-group comparisons 40 (n=18, 35%) (n=19, 39%) 20 (n=5, 10%) (n=3, 6%) 0 No Decrease in SBP 10 mm Hg Decrease in SBP SBP <140 mm Hg at 6 Months SBP=systolic blood pressure. Symplicity HTN-2 Investigators. Lancet. 2010;376:
25 Medication Changes at 6 and 12 Months Post-Renal Denervation RDN (n=47) 6 month 12 months Decrease (# Meds or Dose) 20.9% (9/43) 27.9% (12/43) Increase (# Meds or Dose) 11.6% (5/43) 18.6% (8/43) Crossover (n=35) 6 months post-rdn Decrease (# Meds or Dose) 18.2% (6/33) Increase (# Meds or Dose) 15.2% (5/33) Physicians were allowed to make changes to medications Once the 6 month primary endpoint was reached* *Further analysis of Medications is ongoing
26 Symplicity HTN-2 Trial: Short-Term Procedural Safety No serious device- or procedure-related adverse events Minor complications in 5 of 52 patients: 1 access-site complication (femoral artery pseudoaneurysm); treated with manual compression 1 post-procedural drop in BP 1 urinary tract infection 1 extended hospital admission for assessment of parasthesias 1 case of back pain; treated with pain medication and resolved after 1 month BP=blood pressure. Symplicity HTN-2 Investigators. Lancet. 2010;376:
27 Symplicity HTN-2 Trial: Chronic Safety 43 renal denervation patients underwent CTA, MRA, or duplex evaluation at 6 months No new vascular abnormalities or stenoses at any site of RF delivery 1 possible progression of a preexisting stenosis unrelated to RF treatment; no further therapy warranted Serious Adverse Events at 6 Months Requiring Hospital Admission Composite Cardiovascular Events Symplicity RDN Group (n=49) Control Group (n=51) Hypertensive event unrelated to nonadherence to medication 3 2 Other cardiovascular events 0 0 Other Serious Adverse Events Transient ischemic attack 1 2 Hypertensive crisis after abruptly stopping clonidine 1 0 Hypotensive episode resulting in reduction of medications 1 0 Coronary stent for angina 1 1 Temporary nausea/edema 1 0 CTA=computed tomography angiography; MRA=magnetic resonance angiography; RDN=renal denervation; RF=radiofrequency. Symplicity HTN-2 Investigators. Lancet. 2010;376:
28 Symplicity HTN-2: Renal Function No Significant Differences in Renal Function Observed at 6 Months Renal Function (baseline-6m) Symplicity RDN Group Control Group Difference (95% CI) P Mean egfr ± SD (ml/min/1.73m 2 ) 0.2 ± 11 (n=49) 0.9 ± 12 (n=51) -0.7 (-5.4, 3.9).76 Mean serum creatinine ± SD (μmol/l) 0.2 ± 17.6 (n=49) -1.1 ± 10.3 (n=51) 1.3 (-4.5, 7.0).67 Mean cystatin-c ± SD (mg/l) 0.1 ± 0.2 (n=37) 0.0 ± 0.1 (n=40) 0.0 (0.0, 0.1).31 egfr=estimated glomerular filtration rate; RDN=renal denervation. Symplicity HTN-2 Investigators. Lancet. 2010;376:
29 Symplicity HTN-2: Conclusions Symplicity HTN-2 supports and extends the results of previous uncontrolled evaluations of renal denervation Renal denervation led to a reduction in BP of 10 mm Hg in 84% of treated patients At 6 months, an SBP reduction of 32 mm Hg was observed among renal denervation patients, compared with a 1 mm Hg increase in control patients (P<.0001) Procedure was conducted without major adverse effects No evidence of renal artery stenosis No evidence of aneurysmal dilatation No changes in measured renal function BP=blood pressure; SBP=systolic blood pressure. Symplicity HTN-2 Investigators. Lancet. 2010;376:
30 Symplicity HTN-3 Trial Overview Design Multicenter (90 sites in the United States), prospective, randomized, blinded, controlled study Population 530 patients with treatment-resistant hypertension Treatment Treatment group (endovascular catheter-based renal denervation with the Symplicity Catheter System* plus baseline antihypertensive medications) Control group (sham procedure ** plus baseline antihypertensive medications) Primary Outcome Measures Change in office SBP from baseline to 6 months Safety **The renal angiogram also acts as the sham procedure for patients in the control group. SBP=systolic blood pressure. Data on file, Medtronic, Inc.
31 Symplicity HTN-3 Trial Key Inclusion/Exclusion Criteria* Inclusion criteria Years of age Elevated office SBP ( 160 mm Hg) Stable medication regimen, including full doses of 3 antihypertensive medications of different classes, of which one must be a diuretic No planned medication changes for 6 months Exclusion criteria Renal artery anatomy that is ineligible for treatment ABPM 24-hour average SBP <135 mm Hg egfr <45 ml/min/1.73m 2 >1 In-patient hospitalization for a hypertensive crisis within the past year Type 1 diabetes mellitus *Not comprehensive; full listing of inclusion/exclusion criteria will be available in the Symplicity HTN-3 protocol. ABPM=ambulatory blood pressure; egfr=estimated glomerular filtration rate; SBP=systolic blood pressure. Data on file, Medtronic, Inc.
32 Objectives: Assess procedural and long term safety of renal denervation Evaluate effectiveness of renal denervation on clinical outcomes Establish procedural benchmarking and physician practice patterns Evaluate the effect of geographical variations in patients and procedural characteristics on clinical outcomes Perform Quality of Life analysis First enrollment February 2 nd, 2012 Scope: Over 200 sites world wide; at least 5,000 patients Prospective, single-arm, open-label In accordance with Instructions For Use Geographies with commercial availability of Medtronic Symplicity Renal Denervation System* *device not approved for use in the US
33 What s Next?
34 New renal denervation systems unveiled at EuroPCR Two new denervation systems were launched at EuroPCR (Paris, May 2012). St. Jude Medical announced the launch of the EnligHTN system Covidien unveiled its OneShot system
35 EnligHTN (St. Jude Medical) The first multi-electrode ablation technology for renal denervation Basket design Each placement of the ablation catheter allows a consistent and predictable pattern of four ablations in 90-second intervals Minimal catheter repositioning may result in a reduction of dye and fluoroscopic (X-ray) exposure
36 EnligHTN (St. Jude Medical) The EnligHTN I trial (primary investigator Stephen Worthley) on patients with resistant hypertension Preliminary data presented at EuroPCR Average baseline blood pressure despite being on multiple medications: 176/96mmHg 30 days average BP: 148/87mmHg Reduction in systolic BP <140 mmhg: 41% of patients
37 OneShot system (Covedian) The OneShot device received CE mark clearance in Irrigated, radiofrequency-based balloon catheter Spiral configuration of electrodes allows a single application of radiofrequency inside the artery The irrigated catheter cools the arterial surface with a saline solution Covidien is working on a lower-profile catheter (7F) The system will start being commercialised in the end of 2012
38 RAPID Trial The first patient in the post-ce mark clinical trial, RAPID (Rapid renal sympathetic denervation for resistant hypertension using the OneShot Ablation System) was enrolled at Middleheim Hospital in Antwerp, Belgium, by Stefan Verheye. This trial will enroll subjects throughout Europe and at a site in New Zealand.
39 Thermocool System Cool Flow Pump Stockert RF Generator 7FR Thermocool Catheter CONFIDENTIAL Biosense Webster, Inc Thermocool Irrigated RD Catheter 7FR 3.5mm tip electrode 4 electrodes Saline irrigation 110cm long 39
40 Cooled (Irrigated) Tip Ablation Definition: Active cooling of the electrode tip by infusion of liquid Purpose: To decrease the risk of coagulum formation To spar the tip electrode/tissue interface To maintain the advantages of a small tip electrode
41 Placeholder Pre-Clinical Work 16 Animals 8 With each catheter type Survived for 7 Days Looked at norepi levels and histology 5 lesions per artery 15 Watts 30, 60, 120 second burns CONFIDENTIAL Biosense Webster, Inc. 2011
42 7 day Renal Norepinephrine Levels in Treated and Control Arteries Thermocool (irrigated) #32053 #32054 #32060 # Control Treated 0 Control Treated Two minutes 30 seconds and 1 minute Celsius (nonirrigated) Control Treated #32056 #32057 #32058 # Control Treated
43 Placeholder Human Clinical Data Single Center trial (Relief) - Praque First 10 patients about to be published Follow up(m) No major adverse events 4-6 ablations per artery 10-20W for 30 seconds N Range Mean Median N Range Mean Median to to to to to to CONFIDENTIAL Biosense Webster, Inc. 2011
44 Ultrasound Catheter (Cardiosonic)
45 Results Animal Study
46 Results Animal Study There was clear thermal effect in the artery tissue, mainly presented in the adventitia. Theral effect resulted in collagen condensation in the media and adventitia with necrosis of the vasa-vasorum and nerves. In most sections, the endothelium was left without any damage.
47 Summary RDN of refractory hypertension seems to be effective in a relevant patient population using different devices RDN in other indications is still experimental Besides radiofrequency other technologies will be available soon (cooling, ultrasound, local drug delivery)
Devices and Long-Term Outcomes of Renal Denervation for Hypertension
18th ANGIOPLASTY SUMMIT-TCTAP 2013 Seoul, Korea, April 23-26, 2013 Devices and Long-Term Outcomes of Renal Denervation for Hypertension Horst Sievert, Ilona Hofmann, Laura Vaskelyte, Stefan Bertog, Simon
More informationTreating Hypertension With a Catheter..Wait What? David P. Lee, M.D. 22 June 2013 Stanford University
Treating Hypertension With a Catheter..Wait What? David P. Lee, M.D. 22 June 2013 Stanford University COI Medtronic: Research Grant, Consultant Boston Scientific: Research Grant, MAB Worldwide Prevalence
More informationCatheter-Based Renal Denervation (RDN)
Hypertension lecture 3: Catheter-Based Renal Denervation (RDN) Adapted from slides prepared by Dr IOEBRAHIM, UNITAS HOSPITAL and others Hypertension Epidemiology 30% Untreated 35% Treated & Controlled
More informationCatheter-Based Renal Sympathetic Denervation in the Management of Resistant Hypertension
Catheter-Based Renal Sympathetic Denervation in the Management of Resistant Hypertension Henry Krum, Markus Schlaich, Paul Sobotka, Rob Whitbourn, Jerzy Sadowski, Krzysztof Bartus, Boguslaw Kapelak, Horst
More informationRenal Artery Denervation New Concepts in Hypertension Treatment
Renal Artery Denervation New Concepts in Hypertension Treatment Istanbul Course of Interventional Cardiology J. Weil Medizinische Klinik II Kardiologie, Angiologie und internistische Intensivmedizin Universitätsklinikum,
More informationEnligHTN I, First-in-Human Multicenter Study of a Multi-Electrode Renal Denervation Catheter in Patients with Drug-Resistant Hypertension
EnligHTN I, First-in-Human Multicenter Study of a Multi-Electrode Renal Denervation Catheter in Patients with Drug-Resistant Hypertension Vasilios Papademetriou, MD 1 Prof. Stephen Worthley, MD 2 Costas
More informationWhat We've Learned from Simplicity HTN-1,2, and Registries
ANGIOPLASTY SUMMIT-TCTAP 2012 Seoul, Korea, April 24-27, 2012 What We've Learned from Simplicity HTN-1,2, and Registries Horst Sievert, Ann-Kathrin Ziegler, Benjamin Kaltenbach, Ilona Hofmann, Undine Pittl
More informationTreating Hypertension With a Catheter..Wait What? COI 5/3/2013. Worldwide Prevalence of Hypertension Is Increasing
Treating Hypertension With a Catheter..Wait What? David P. Lee, M.D. 4 May 2013 Stanford University COI Medtronic: Research Grant, Consultant Boston Scientific: Research Grant, MAB Worldwide Prevalence
More informationStephen G. Worthley 1, Gerard T. Wilkins 2, Mark W. Webster 3,Joseph K. Montarello 1, Paul T. Antonis 4, Robert J. Whitbourn 5, Roderic J.
Six Month Results of First-in-Human Sympathetic Renal Artery Denervation Using a Next Generation Multi-Electrode Renal Artery Denervation System in Patients with Drug-Resistant Hypertension Stephen G.
More informationReal World Experience with Renal Denervation Therapy
JCR 2013 Real World Experience with Renal Denervation Therapy Seung-Hyuk Choi Division of Cardiology Samsung Medical Center Seoul, Korea Hypertension A Major Public Health Burden Astonishing prevalence
More informationCatheter-Based Renal Denervation Reduces Total Body and Renal Noradrenaline Spillover and Blood Pressure in Resistant Hypertension
Catheter-Based Renal Denervation Reduces Total Body and Renal Noradrenaline Spillover and Blood Pressure in Resistant Hypertension Murray Esler, Markus Schlaich, Paul Sobotka, Rob Whitbourn, Jerzy Sadowski,
More informationRenal Sympathetic Denervation for HTN
Renal Sympathetic Denervation for HTN Se-Young Yim Department of CardioVascular Center Samsung Medical Center Worldwide Prevalence of Hypertension Is Increasing In 2000, 972 million (26%), of the adult
More informationRISE, FALL AND RESURRECTION OF RENAL DENERVATION. Michael A. Weber, MD State University of New York Downstate College of Medicine
RISE, FALL AND RESURRECTION OF RENAL DENERVATION Michael A. Weber, MD State University of New York Downstate College of Medicine Michael Weber, Disclosures Research/Trial Commitments and Consulting: Boston
More informationRadiofrequency Energy Provides Safe & Durable Blood Pressure Reduction: Complete 3 Year Results from Symplicity HTN-1
Radiofrequency Energy Provides Safe & Durable Blood Pressure Reduction: Complete 3 Year Results from Symplicity HTN-1 Henry Krum MBBS PhD FRACP FESC for the Symplicity I Investigators CCRE Therapeutics,
More informationByeong-Keuk Kim, MD, PhD. Division of Cardiology, Severance Cardiovascular Hospital Yonsei University College of Medicine, Seoul, Korea
Byeong-Keuk Kim, MD, PhD Division of Cardiology, Severance Cardiovascular Hospital Yonsei University College of Medicine, Seoul, Korea BP change (mmhg) from Baseline to 6 Months (mmhg) Catheter-based renal
More informationPreliminary Results of RETREAT
LINC 2015 Leipzig, Germany, Jan 27-30, 2015 Preliminary Results of RETREAT (Renal Denervation with Ultrasound After Failed Radiofrequency Denervation) Horst Sievert, Jan Philipp Kulow, Stefan Bertog, Predrag
More informationRenal denervation: Current evidence and remaining uncertainties
Renal denervation: Current evidence and remaining uncertainties Michel Azizi Georges Pompidou European Hospital Hypertension Unit ESH excellence Center Paris Descartes University Clinical Investigation
More informationRenal Denervation for Resistant Hypertension
Renal Denervation for Resistant Hypertension James W. Choi MD FACC FSCAI Cardiology Consultants of Texas Director Interventional Cardiology Fellowship Baylor University Medical Center Baylor Heart & Vascular
More informationChristopher Valentine, MD
Resistant Hypertension Christopher Valentine, MD Program Director, Nephrology Fellowship Program Department of Internal Medicine Division of Nephrology The Ohio State University Wexner Medical Center Disclosures
More informationRenal Sympathetic Denervation for Treatment of Resistant Hypertension: 18-Month Results from the Symplicity HTN-2 Randomized Controlled Trial
Renal Sympathetic Denervation for Treatment of Resistant Hypertension: 18-Month Results from the Symplicity HTN-2 Randomized Controlled Trial Prof Murray Esler Baker IDI Heart and Diabetes Institute, Melbourne
More informationAutumn Meeting Birmingham. Renal Denervation
Autumn Meeting Birmingham Renal Denervation Andreas Baumbach, MD, FRCP, FESC Consultant Cardiologist, hon. Reader in Cardiology Bristol Heart Institute University Hospitals Bristol Renal Denervation BACKGROUND
More informationnoradrenaline spillover and systemic blood pressure in patients with resistant hypertension
Effects of renal sympathetic denervation on noradrenaline spillover and systemic blood pressure in patients with resistant hypertension Markus Schlaich Neurovascular Hypertension & Kidney Disease Laboratory
More informationRenal Denervation For Hypertension: Status Update
Samuel N. Steerman, Presenter MD, FACS, name RPVI EVMS Assistant Professor of Surgery Sentara Vascular Specialists Renal Denervation For Hypertension: Status Update Disclosures Disclosures Speaker s Panel
More informationCATHETER-BASED RENAL DENERVATION INCREASES INSULIN SENSITIVITY AND IMPROVES GLUCOSE METABOLISM IN PATIENTS WITH RESISTANT HYPERTENSION
CATHETER-BASED RENAL DENERVATION INCREASES INSULIN SENSITIVITY AND IMPROVES GLUCOSE METABOLISM IN PATIENTS WITH RESISTANT HYPERTENSION F. Mahfoud, Ch. Ukena, B. Cremers, I. Kindermann, M. Kindermann, P.
More informationRenal Denervation: The Case for Cardiology
Renal Denervation: The Case for Cardiology John C. Gurley, MD University of Kentucky Presenter Disclosure Information John C Gurley, MD Renal Denervation: The Case for Cardiology FINANCIAL DISCLOSURE:
More informationThe Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation In Real World Patients With Uncontrolled Hypertension
The Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation In Real World Patients With Uncontrolled Hypertension Michael Böhm, MD on behalf of the GSR Investigators March 30,
More informationRenal Denervation. Henry Krum MBBS PhD FRACP. Centre of Cardiovascular Research & Monash University/Alfred Hospital;
Renal Denervation Henry Krum MBBS PhD FRACP Centre of Cardiovascular Research & Education in Therapeutics, Monash University/Alfred Hospital; Alfred Heart Centre, The Alfred Hospital, Melbourne Australia
More informationWith an unrestricted educational grant from. The Interventional Treatment of Resistant Hypertension
With an unrestricted educational grant from The Interventional Treatment of Resistant Hypertension Felix Mahfoud Interventional Cardiology University Hospital Homburg/Saar Germany Dr. Mahfoud graduated
More informationThe Future of Renal Denervation
The Future of Renal Denervation Ron Waksman, MD, FACC, FSCAI Professor of Medicine, (Cardiology) Georgetown University Director, Cardiovascular Research Advanced Education MedStar Heart Institute, Washington
More informationManagement of Resistant Hypertension in Diabetes
Management of Resistant Hypertension in Diabetes Soon Hee Lee, M.D., Ph.D. Divisoin of Endocrinology & Metabolism, Department of Internal Medicine, Busan Paik Hospital, College of Medicine, Inje University,
More informationRenal Sympathetic Denervation Beyond Hypertension: Therapy for Arrhythmias and for Autonomic Nervous System Dysfunction?
Renal Sympathetic Denervation Beyond Hypertension: Therapy for Arrhythmias and for Autonomic Nervous System Dysfunction? Vivek Y. Reddy, MD Helmsley Trust Professor of Medicine Director, Cardiac Arrhythmia
More informationΣύγτρονη θεραπεία της ανθεκτικής σπέρτασης
Σύγτρονη θεραπεία της ανθεκτικής σπέρτασης Κώζηας Τζιούθης Α Παν/κή Καρ/κή Κλινική Ιπποκράηειο Γ.Ν.Α. Resistant or Refractory to treatment Hypertension Office BP>140/90 or 130/80 mm Hg in patients with
More informationDisclosures for Dr. Bhatt
Renal Denervation Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC Executive Director of Interventional Cardiovascular Programs, BWH Heart & Vascular Center Professor of Medicine, Harvard Medical School
More informationTranscatheter Renal Denervation and Hong Kong Experience
Transcatheter Renal Denervation and Hong Kong Experience Dr. Steven Li Siu-lung FACC, FESC, FRCP, FACP Director, Heart Centre, Union Hospital President, Hong Kong Society of Congenital and Structural Heart
More informationTranscatheter Perivascular Alcohol- Mediated Renal Denervation
Transcatheter Perivascular Alcohol- Mediated Renal Denervation Wojtek Wojakowski, MD, PhD Medical University of Silesia American Heart of Poland Katowice, Poland I, Wojciech Wojakowski DO NOT have a financial
More informationΦαρµακευτική θεραπεία υπερτασικών ασθενών. Δ. Τσιαχρής, Καρδιολόγος, Α Πανεπιστηµαική Καρδιολογική Κλινική
Φαρµακευτική θεραπεία υπερτασικών ασθενών Δ. Τσιαχρής, Καρδιολόγος, Α Πανεπιστηµαική Καρδιολογική Κλινική A 42-Year-Old Female with True Severe Resistant Hypertension Female, 42 years old, smoker BMI:
More informationNeuromodulation Device Therapy for Treatment of Hypertensive Heart Disease
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp REVIEW Neuromodulation Device Therapy for Treatment of Hypertensive Heart Disease Thomas M. Todoran, MD;
More informationCatheter Based Denervation for Heart Failure
Catheter Based Denervation for Heart Failure David E. Kandzari, MD, FACC, FSCAI Chief Scientific Officer Director, Interventional Cardiology Piedmont Heart Institute Atlanta, Georgia david.kandzari@piedmont.org
More informationRenal denervation for treatment of resistant hypertension
Renal denervation for treatment of resistant hypertension Dr U. Nqebelele Division of Nephrology Department of Internal Medicine Charlotte Maxeke Johannesburg Academic Hospital Thomas Willis: 1621-1675
More informationMP Radiofrequency Ablation of the Renal Sympathetic Nerves as a Treatment for Resistant Hypertension
Medical Policy Radiofrequency Ablation of the Renal Sympathetic Nerves as a Treatment for Resistant Hypertension BCBSA Ref. Policy: 7.01.136 Last Review: 09/19/2018 Effective Date: 09/19/2018 Section:
More information신장환자의혈압조절 나기영. Factors involved in the regulation of blood pressure
신장환자의혈압조절 K/DOQI Clinical practice guidelines on Hypertension and Antihypertensive agents in CKD 나기영 Factors involved in the regulation of blood pressure Renal function curve MAP (mmhg) Central role of
More informationOLOMOUC I Study M. Táborský, M. Lazárová, J. Václavík, D. Richter ESC 2012, Munich,
The effect of renal denervation in patients with advanced heart failure: OLOMOUC I Study M. Táborský, M. Lazárová, J. Václavík, D. Richter ESC 2012, Munich, 27.08.2012 Disclosures MT: honoraria Bayer,
More informationCoral Trials: A personal experience that challenges its results in patients with uncontrolled blood pressure.
Coral Trials: A personal experience that challenges its results in patients with uncontrolled blood pressure.. Dr. Javier Ruiz Aburto, FACS, FICS Assistant Professor Ponce School of Medicine Puerto Rico
More informationSPYRAL HTN ON MED. Disclosure
Renal Denervation in the Presence of Antihypertensive Medications: Six-month Results from the Randomized, Blinded, Sham-controlled SPYRAL HTN-ON MED Trial Dr. David E. Kandzari Piedmont Heart Institute,
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationRenal Sympathetic Denervation Using an Irrigated Radiofrequency Ablation Catheter for the Management of Drug-Resistant Hypertension
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 5, NO. 7, 2012 2012 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcin.2012.01.027
More informationDr Doris M. W Kinuthia
Dr Doris M. W Kinuthia Objectives Normal blood pressures in children Measurement of blood pressure in children Aetiology of Hypertension in children Evaluation of children with hypertension Treatment of
More informationUpdate on renal denervation: Latest data
LINC 2018 Update on renal denervation: Latest data Felix Mahfoud Saarland University Hospital, Germany Potential Conflicts of Interest I have the following potential conflicts of interest to report: Research
More informationManagement of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine
Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing
More informationRenal Sympathetic Denervation in the Treatment of Resistant Hypertension: Current Clinical Evidence, Patient Selection, Tips and Tricks
Renal Sympathetic Denervation in the Treatment of Resistant Hypertension: Current Clinical Evidence, Patient Selection, Tips and Tricks Kostadin Kichukov, MD, PhD, Iskren Garvanski MD, Department cardiology,
More informationProf. Andrzej Wiecek Department of Nephrology, Endocrinology and Metabolic Diseases Medical University of Silesia Katowice, Poland.
What could be the role of renal denervation in chronic kidney disease? Andrzej Wiecek, Katowice, Poland Chairs: Peter J. Blankestijn, Utrecht, The Netherlands Jonathan Moss, Glasgow, UK Prof. Andrzej Wiecek
More informationRenal Denervation. by Walead Latif, DO, MBA, CPE Assistant Clinical Professor Rutgers Medical School
Renal Denervation by Walead Latif, DO, MBA, CPE Assistant Clinical Professor Rutgers Medical School Disclosure Information ACOI Annual Meeting I have the following financial relationships to disclose:
More informationClinical Policy Title: Renal denervation
Clinical Policy Title: Renal denervation Clinical Policy Number: 09.03.04 Effective Date: February 1, 2017 Initial Review Date: November 16, 2016 Most Recent Review Date: January 11, 2018 Next Review Date:
More informationSupplementary Online Content
Supplementary Online Content Xu X, Qin X, Li Y, et al. Efficacy of folic acid therapy on the progression of chronic kidney disease: the Renal Substudy of the China Stroke Primary Prevention Trial. JAMA
More informationLife After CORAL: What Did CORAL Prove? David Paul Slovut, MD, PhD Co-director TAVR, Dir of Advanced Intervention
Life After CORAL: What Did CORAL Prove? David Paul Slovut, MD, PhD Co-director TAVR, Dir of Advanced Intervention No Relationships to Disclose The Need for Modern Renal Trials Increased rate of RAS diagnosis
More informationMINNEAPOLIS September 12, 2012 Medtronic, Inc. (NYSE: MDT) today announced findings
NEWS RELEASE Contacts: Wendy Dougherty Jeff Warren Public Relations Investor Relations 707-541-3004 763-505-2696 FOR IMMEDIATE RELEASE HEALTH-ECONOMIC ANALYSIS SUGGESTS MEDTRONIC SYMPLICITY RENAL DENERVATION
More informationHypertension: the Heart Vs the Kidney. George Moturi Physician/Nephrologist Aga Khan Hospital Nairobi
Hypertension: the Heart Vs the Kidney George Moturi Physician/Nephrologist Aga Khan Hospital Nairobi 24 th Feb, 2017 Travel facilitation from Novartis Disclaimer Systolic blood pressure (SBP) of at least
More informationFinal Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
More informationMasahiko Fujihara, MD
Verify the efficacy of renal artery stenting to define the predictive factors by physiological assessment with pressure wire gradient VERDICT study Masahiko Fujihara, MD Kishiwada Tokushukai Hospital Osaka,
More informationReframe the Paradigm of Hypertension treatment Focus on Diabetes
Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016 Overview Physiopathology of hypertension Classification
More informationFinal Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationThe Role of Lithotripsy in Solving the Challenges of Vascular Calcium. Thomas Zeller, MD
The Role of Lithotripsy in Solving the Challenges of Vascular Calcium Thomas Zeller, MD 1 1 Disclosure Speaker name: Thomas Zeller... I have the following potential conflicts of interest to report: X X
More informationHypertension Guidelines Michael A. Weber, MD Division of Cardiovascular Medicine State University of New York Downstate Medical Center
Hypertension Guidelines 2016 Michael A. Weber, MD Division of Cardiovascular Medicine State University of New York Downstate Medical Center Speaker Disclosures I disclose that I am a Consultant for: Ablative
More informationCirculation. Blood Pressure and Antihypertensive Medications. Venous Return. Arterial flow. Regulation of Cardiac Output.
Circulation Blood Pressure and Antihypertensive Medications Two systems Pulmonary (low pressure) Systemic (high pressure) Aorta 120 mmhg Large arteries 110 mmhg Arterioles 40 mmhg Arteriolar capillaries
More informationRadiofrequency Ablation of the Renal Sympathetic Nerves as a Treatment for Resistant Hypertension
Last Review Status/Date: December 2014 Page: 1 of 18 Nerves as a Treatment for Resistant Hypertension Description Radiofrequency ablation (RFA) of the renal sympathetic nerves is a non-pharmacologic treatment
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationRENAL SYMPATHETIC DENERVATION PAST, PRESENT AND FUTURE
RENAL SYMPATHETIC DENERVATION THE ROLE OF THE SYMPATHETIC NERVOUS SYSTEM PAST, PRESENT AND FUTURE Dr RS DAWOOD DEPARTMENT OF CARDIOLOGY CHRIS HANI BARAGWANATH ACADEMIC HOSPITAL SATURDAY 02/08/2014 FACT
More informationEffective Health Care
Number 5 Effective Health Care Comparative Effectiveness of Management Strategies for Renal Artery Stenosis Executive Summary Background Renal artery stenosis (RAS) is defined as the narrowing of the lumen
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More informationRenal sympathetic denervation as a potential treatment for hypertension
Renal sympathetic denervation as a potential treatment for hypertension (Why we must keep going) Dr Andrew SP Sharp Consultant Cardiologist and Honorary Senior Lecturer Royal Devon and Exeter Hospital
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationHYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL
HYPERTENSION IN CKD LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL Stages in Progression of Chronic Kidney Disease and Therapeutic Strategies Complications Normal Increased risk Damage GFR
More informationTAVR 肾动脉去交感神经治疗顽固性高血压 对第三代 DES 的评价 新的药物
ACC 2012 亮点 TAVR 肾动脉去交感神经治疗顽固性高血压 对第三代 DES 的评价 新的药物 TAVR 肾动脉去交感神经治疗顽固性高血压 对第三代 DES 的评价 新的药物 Axel Linke University of Leipzig Heart Center, Leipzig, Germany Ulrich Gerckens Gemeinschaftskrankenhaus Bonn,
More informationPatient safety in the Eluvia DES and Ranger DCB programmes
Patient safety in the Eluvia DES and Ranger DCB programmes William A. Gray, MD Lankenau Heart Institute, Wynnewood, PA, USA Jan 22, 2019 Room 1 - Main Arena Disclosure Speaker name: William Gray I have
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationCORAL Trial Aftermath: What Do We Do Now? Renal Revascularization in Perspective
CORAL Trial Aftermath: What Do We Do Now? Renal Revascularization in Perspective Michael R. Jaff, DO Massachusetts General Hospital Boston, Massachusetts, USA Michael R. Jaff, DO Conflicts of Interest
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationHypertensives Emergency and Urgency
Hypertensives Emergency and Urgency Budi Yuli Setianto Cardiology Divisision Department of Internal Medicine Faculty of Medicine UGM Sardjito Hospital Yogyakarta Background USA: Hypertension is 30% of
More informationUpdate on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
More informationhypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationBlood Pressure Management in Acute Ischemic Stroke
Blood Pressure Management in Acute Ischemic Stroke Kimberly Clark, PharmD, BCCCP Clinical Pharmacy Specialist Critical Care, Greenville Health System Adjunct Assistant Professor, South Carolina College
More informationByvalson. (nebivolol, valsartan) New Product Slideshow
Byvalson (nebivolol, valsartan) New Product Slideshow Introduction Brand name: Byvalson Generic name: Nebivolol, valsartan Pharmacological class: Beta-blocker + angiotensin II receptor blocker (ARB) Strength
More informationManagement of High Blood Pressure in Adults
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) James, P. A. (2014, February 05). 2014 Guideline for Management
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationM2 TEACHING UNDERSTANDING PHARMACOLOGY
M2 TEACHING UNDERSTANDING PHARMACOLOGY USING CVS SYSTEM AS AN EXAMPLE NIGEL FONG 2 JAN 2014 TODAY S OBJECTIVE Pharmacology often seems like an endless list of mechanisms and side effects to memorize. To
More information2-YEAR DATA SUPERA POPLITEAL REAL WORLD
2-YEAR DATA SUPERA POPLITEAL REAL WORLD Enrique M. San Norberto. Angiology and Vascular Surgery. Valladolid University Hospital. Valladolid. Spain. Disclosure Speaker name: ENRIQUE M. SAN NORBERTO I have
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationHypertension. Penny Mosley MRPharmS
Hypertension Penny Mosley MRPharmS Outline of presentation Introduction to hypertension Physiological control of arterial blood pressure What determines our bp? What determines the heart rate? What determines
More informationDEPARTMENT OF GENERAL MEDICINE WELCOMES
DEPARTMENT OF GENERAL MEDICINE WELCOMES 1 Dr.Mohamed Omar Shariff, 2 nd Year Post Graduate, Department of General Medicine. DR.B.R.Ambedkar Medical College & Hospital. 2 INTRODUCTION Leading cause of global
More informationRenal Denervation Using an Irrigated Catheter in Patients with Resistant Hypertension: A Promising Strategy?
Renal Denervation Using an Irrigated Catheter in Patients with Resistant Hypertension: A Promising Strategy? Luciana Armaganijan, Rodolfo Staico, Aline Moraes, Alexandre Abizaid, Dalmo Moreira, Celso Amodeo,
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationCopyright 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Normal Cardiac Anatomy
Mosby,, an affiliate of Elsevier Normal Cardiac Anatomy Impaired cardiac pumping Results in vasoconstriction & fluid retention Characterized by ventricular dysfunction, reduced exercise tolerance, diminished
More informationVascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital
Vascular disease. Structural evaluation of vascular disease Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital resistance vessels : arteries
More information